Bank of America’s ProQR Therapeutics PRQR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $300K | Buy |
185,110
+11,186
| +6% | +$18.3K | ﹤0.01% | 5153 |
|
|
2025
Q4 | $351K | Buy |
173,924
+54,726
| +46% | +$128K | ﹤0.01% | 5094 |
|
|
2025
Q3 | $254K | Hold |
119,198
| – | – | ﹤0.01% | 6163 |
|
|
2025
Q2 | $243K | Buy |
119,198
+24,347
| +26% | +$39.6K | ﹤0.01% | 6088 |
|
|
2025
Q1 | $126K | Buy |
94,851
+13,067
| +16% | +$27.8K | ﹤0.01% | 6390 |
|
|
2024
Q4 | $217K | Buy |
81,784
+8,621
| +12% | +$27.4K | ﹤0.01% | 6082 |
|
|
2024
Q3 | $133K | Hold |
73,163
| – | – | ﹤0.01% | 6204 |
|
|
2024
Q2 | $121K | Sell |
73,163
-36,944
| -34% | -$71.7K | ﹤0.01% | 6165 |
|
|
2024
Q1 | $252K | Buy |
110,107
+31,854
| +41% | +$68.1K | ﹤0.01% | 5770 |
|
|
2023
Q4 | $155K | Sell |
78,253
-30,085
| -28% | -$46.2K | ﹤0.01% | 6207 |
|
|
2023
Q3 | $141K | Sell |
108,338
-46,148
| -30% | -$72.6K | ﹤0.01% | 6092 |
|
|
2023
Q2 | $250K | Buy |
154,486
+1,555
| +1% | +$3.04K | ﹤0.01% | 5694 |
|
|
2023
Q1 | $326K | Buy |
152,931
+120,566
| +373% | +$369K | ﹤0.01% | 5651 |
|
|
2022
Q4 | $120K | Buy |
32,365
+12
| +0% | +$16 | ﹤0.01% | 6164 |
|
|
2022
Q3 | $24K | Sell |
32,353
-2,154
| -6% | -$1.73K | ﹤0.01% | 6964 |
|
|
2022
Q2 | $27K | Buy |
34,507
+14,946
| +76% | +$11.1K | ﹤0.01% | 7087 |
|
|
2022
Q1 | $18K | Sell |
19,561
-168,335
| -90% | -$564K | ﹤0.01% | 7562 |
|
|
2021
Q4 | $1.51M | Buy |
187,896
+113,558
| +153% | +$865K | ﹤0.01% | 4838 |
|
|
2021
Q3 | $622K | Buy |
74,338
+72,720
| +4,494% | +$475K | ﹤0.01% | 5469 |
|
|
2021
Q2 | $11K | Sell |
1,618
-20,551
| -93% | -$133K | ﹤0.01% | 7278 |
|
|
2021
Q1 | $147K | Buy |
22,169
+18,895
| +577% | +$96.5K | ﹤0.01% | 6230 |
|
|
2020
Q4 | $14K | Sell |
3,274
-21,276
| -87% | -$89.8K | ﹤0.01% | 6661 |
|
|
2020
Q3 | $118K | Buy |
+24,550
| New | +$128K | ﹤0.01% | 5603 |
|
|
2020
Q1 | – | Sell |
-232
| Closed | -$2K | – | 7158 |
|
|
2019
Q4 | $2K | Buy |
+232
| New | +$1.81K | ﹤0.01% | 6896 |
|
|
2019
Q3 | – | Sell |
-2,740
| Closed | -$24K | – | 7457 |
|
|
2019
Q2 | $24K | Buy |
2,740
+1,648
| +151% | +$19.4K | ﹤0.01% | 6527 |
|
|
2019
Q1 | $15K | Sell |
1,092
-798
| -42% | -$11.9K | ﹤0.01% | 6563 |
|
|
2018
Q4 | $29K | Buy |
1,890
+1,640
| +656% | +$30.1K | ﹤0.01% | 6389 |
|
|
2018
Q3 | $5K | Hold |
250
| – | – | ﹤0.01% | 6834 |
|
|
2018
Q2 | $2K | Hold |
250
| – | – | ﹤0.01% | 6918 |
|
|
2018
Q1 | $1K | Buy |
+250
| New | +$804 | ﹤0.01% | 6979 |
|
|
2015
Q1 | – | Sell |
-100
| Closed | -$2K | – | 7445 |
|
|
2014
Q4 | $2K | Buy |
+100
| New | +$1.52K | ﹤0.01% | 7490 |
|
Other funds holding PRQR
PFM
AAA
SCM
DCM
KCM
IC
PIM
Bank of America's PRQR Position: Q1 2026 in Review
Bank of America increased its ProQR Therapeutics (PRQR) stake by 6.4% in Q1 2026, buying an estimated $18.3K and bringing the position to 185,110 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #5153.
Bank of America first reported a position in PRQR in Q4 2014 and has held it in 31 quarters since. The position peaked at $1.51M in Q4 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.
- Bank of America held 185,110 shares of ProQR Therapeutics worth $300K as of Q1 2026.
- Bank of America bought 11,186 ProQR Therapeutics shares in Q1 2026, an estimated $18.3K.
- ProQR Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5153 holding.
- Bank of America first reported a position in ProQR Therapeutics in Q4 2014 and has held it in 31 quarters since.
- Bank of America's ProQR Therapeutics position peaked at $1.51M in Q4 2021.
- 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.